Adagen
information and resources from the National Cancer Institute
|
|
|
|
news articles
Enzon reports substantial loss Feb 28, 2006
MarketWatch Enzon said that it now sees its four leading products--- Abelcet, Adagen, Depocyt and Oncaspar -- having combined 2006 revenues of greater than $100 million, vs ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Genetic Engineering News, ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ADAGEN(R), DEPOCYT(R), and ONCASPAR(R) in North America. In ...
Enzon battered, but execs put on brave face Feb 28, 2006
Newark Star Ledger, ..."We recognize the ongoing challenges in this market.". The company also suffered a lesser slip in its No. 2 product from a year ago, Adagen. ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Finanzen.net, ...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ADAGEN(R),DEPOCYT(R), and ...
Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
Finanzen.net, ...segmentfor 2006. This segment is currently comprised of its four marketedproducts, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ...
Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
Genetic Engineering News, ...segment for 2006. This segment is currently comprised of its four marketed products, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ...
|
|
